Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 14Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1

Interventions

Specimen Handling 7Biopsy 6Cyclophosphamide 5ruxolitinib 4Mycophenolic Acid 4Busulfan 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Tacrolimus 3Melphalan 3Injections 3Decitabine 3Cyclosporine 3Azacitidine 3venetoclax 2decitabine and cedazuridine drug combination 2Sirolimus 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1onvansertib 1merphos 1iadademstat 1gilteritinib 1fedratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × decitabine and cedazuridine drug combination × 1 year × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡